BofA polls show that 70% of patients are comfortable with the autoinjector
The 48-week extension trial (TIPO-4) demonstrated sustained efficacy, with participants maintaining a total mean weight loss of 13-14kg over the extended treatment period, confirming long-term effectiveness without significant tolerance development
However, under federal law, Medicare cannot cover these drugs for weight loss
This dual-action mechanism is a key distinguishing feature of tirzepatide , setting it apart from other weight-loss and diabetes drugs, like Ozempic or Wegovy, that can target only one of these two hormones and, therefore, only one aspect of metabolic regulation
We serve Highland, Poughkeepsie, and surrounding Hudson Valley communities with mobile and in-lounge care.
Animal models show microbiota changes prior to motor symptoms, and probiotic interventions have improved GI and non-motor symptoms in clinical trials